AU6973194A - Composition for ophthalmic use - Google Patents

Composition for ophthalmic use

Info

Publication number
AU6973194A
AU6973194A AU69731/94A AU6973194A AU6973194A AU 6973194 A AU6973194 A AU 6973194A AU 69731/94 A AU69731/94 A AU 69731/94A AU 6973194 A AU6973194 A AU 6973194A AU 6973194 A AU6973194 A AU 6973194A
Authority
AU
Australia
Prior art keywords
composition
ophthalmic use
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69731/94A
Inventor
Sakari Alaranta
Hannu Hanhijarvi
Tomi Jarvinen
Kari Lehmussaari
Olli Oksala
Esko Pohjala
Timo Reunamaki
Pekka Suhonen
Arto Urtti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Oy
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of AU6973194A publication Critical patent/AU6973194A/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU69731/94A 1993-06-24 1994-06-17 Composition for ophthalmic use Abandoned AU6973194A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9302203 1993-06-24
SE9302203A SE501482C2 (en) 1993-06-24 1993-06-24 Composition for topical administration of bispilocarpic acid diesters to the eye in the form of an aqueous solution
PCT/FI1994/000270 WO1995000144A1 (en) 1993-06-24 1994-06-17 Composition for ophthalmic use

Publications (1)

Publication Number Publication Date
AU6973194A true AU6973194A (en) 1995-01-17

Family

ID=20390417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69731/94A Abandoned AU6973194A (en) 1993-06-24 1994-06-17 Composition for ophthalmic use

Country Status (5)

Country Link
AU (1) AU6973194A (en)
EE (1) EE9400040A (en)
LT (1) LT3525B (en)
SE (1) SE501482C2 (en)
WO (1) WO1995000144A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977180A (en) * 1994-07-11 1999-11-02 Pate; David W. Anandamide analog compositions and method of treating intraocular hypertension using same
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
WO2023225113A1 (en) * 2022-05-18 2023-11-23 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58126810A (en) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd Ophthalmic anti-inflammatory solution and preparation thereof
TW200402B (en) * 1990-08-13 1993-02-21 Senju Pharma Co
FI98815C (en) * 1990-11-30 1997-08-25 Santen Oy Process for the preparation of new pharmacologically useful ester derivatives of bispilocarpic acid

Also Published As

Publication number Publication date
SE501482C2 (en) 1995-02-27
WO1995000144A1 (en) 1995-01-05
LT3525B (en) 1995-11-27
EE9400040A (en) 1995-12-15
LTIP1970A (en) 1995-01-31
SE9302203L (en) 1994-12-25
SE9302203D0 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
IL115479A0 (en) Composition for ophthalmic use
AU7533894A (en) Cosmetic composition
AU1072695A (en) Dressing
AU7612494A (en) Cosmetic composition
AU5794094A (en) Tricritical point composition
ZA948961B (en) Ophthalmic formulation
AU1248395A (en) Bandages
AU7309394A (en) Disinfectant composition
AU650351B2 (en) Ophthalmic compositions
AU7589394A (en) Leavening composition
AU6000794A (en) Cleansing composition
AU7653294A (en) Shaving composition
AU7836794A (en) New cytotoxic agents
AU7437094A (en) Disinfectant-detergent composition
AU6571594A (en) Thioindole pyperidinyl derivatives used as antalgics
AU5773994A (en) Cable-making compositions
AU665084B2 (en) Rubber composition
AU6337294A (en) Ophthalmic topical agent
AU6544294A (en) Polystyrene-dissolving agent
AU6511294A (en) Tonometer
AU5888094A (en) Adjustable spectacles
AU8149294A (en) Disinfectant composition
AU672124B2 (en) Composition
AU6973194A (en) Composition for ophthalmic use
AU6021794A (en) Ophthalmic compositions comprising benzyllauryldimethylammonium chloride